Clyra Bio Information

Clyra is building blood tests that track how the tumor microenvironment (TME) responds to immunotherapy and other cancer treatments. Immunotherapy acts through the TME, yet the TME is usually assessed from a single biopsy taken before treatment, and most blood tests today measure tumor burden alone. Clyra combines complementary molecular layers from routine blood draws to read both which cells make up the TME and what they are doing, at every visit. We partner with biopharma teams to track response and resistance during treatment, inform patient selection, and support companion diagnostic development.